BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...has raised £275 million ($359 million) to operate as a “preferred investor” in spinouts from Cambridge University.Cambridge...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...platform trial Another multitherapeutic COVID-19 trial with an immune focus was launched this week by Cambridge University...
...#), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 BARDA Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum Therapeutics Inc. Palatin Technologies Inc. AstraZeneca plc Cambridge University covid-19 cov19count cov19count...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Aug 26, 2019
Company News

Simone Fishburn announced as BioCentury’s new Editor in Chief

...Ph.D. in molecular pharmacology from the Weizmann, and an M.A. and B.A. in pharmacology from Cambridge University...
BioCentury | May 24, 2019
Finance

Europe: Some spots hotter than others

Led by the U.K., various regions in Europe are raising their profile as hotspots of innovation. But as other areas lose ground, local VCs are raising fresh capital and building the infrastructure needed to boost...
BioCentury | Apr 1, 2019
Finance

Backing Cambridge's AI boom

...has been deployed in the life sciences. As CIC cornerstone investors, University of Cambridge and Cambridge University...
BioCentury | Apr 1, 2019
Financial News

Cambridge Innovation raises £150M

...the firm to invest for the next two to three years. University of Cambridge and Cambridge University...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...U.S. and a single one in Europe -- Cell Mogrify Ltd., which spun out of Cambridge University...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and worm studies suggest the PTP-1B inhibitor trodusquemine could help treat AD. In human cells cultured with β amyloid 42 (Aβ 42 ), trodusquemine decreased the formation of Aβ...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
Items per page:
1 - 10 of 72
BioCentury | Aug 14, 2020
Finance

OSI leverages foundational deal with Oxford to build its life sciences portfolio

...has raised £275 million ($359 million) to operate as a “preferred investor” in spinouts from Cambridge University.Cambridge...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...platform trial Another multitherapeutic COVID-19 trial with an immune focus was launched this week by Cambridge University...
...#), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 BARDA Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum Therapeutics Inc. Palatin Technologies Inc. AstraZeneca plc Cambridge University covid-19 cov19count cov19count...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Aug 26, 2019
Company News

Simone Fishburn announced as BioCentury’s new Editor in Chief

...Ph.D. in molecular pharmacology from the Weizmann, and an M.A. and B.A. in pharmacology from Cambridge University...
BioCentury | May 24, 2019
Finance

Europe: Some spots hotter than others

Led by the U.K., various regions in Europe are raising their profile as hotspots of innovation. But as other areas lose ground, local VCs are raising fresh capital and building the infrastructure needed to boost...
BioCentury | Apr 1, 2019
Finance

Backing Cambridge's AI boom

...has been deployed in the life sciences. As CIC cornerstone investors, University of Cambridge and Cambridge University...
BioCentury | Apr 1, 2019
Financial News

Cambridge Innovation raises £150M

...the firm to invest for the next two to three years. University of Cambridge and Cambridge University...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

...U.S. and a single one in Europe -- Cell Mogrify Ltd., which spun out of Cambridge University...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and worm studies suggest the PTP-1B inhibitor trodusquemine could help treat AD. In human cells cultured with β amyloid 42 (Aβ 42 ), trodusquemine decreased the formation of Aβ...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
Items per page:
1 - 10 of 72